Clinical trial NCT05892952: IONA Longitudinal Cohort Study
Official title: IONA Longitudinal Cohort Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Alzheimer Disease
Dementia
Keywords: cohort study
Alzheimer Disease
Dementia
Lead sponsor: Brain Health Scotland Life Sciences Ltd
Sponsor class: INDUSTRY
First posted: 2023-06-07
Enrollment: 10000
Sex: ALL
Minimum age (years): 50
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The IONA LCS is designed to be inclusive and from within this diverse population smaller sub-populations will be derived. Given the main objective of the programme, the study is open to people over the age of 50 who range from having no symptoms of neurodegenerative disease to those living with a dementia syndrome at the mild stage of illness. All participants will have the capacity to consent to the study at the baseline. Participants who develop moderate-to-severe dementia, and those who lose capacity to provide informed consent during the study, will remain in the study to ensure disease models can capture the full trajectories of these diseases. Recruitment strategies will be designed using the above five sources to ensure all people representative of the Scottish population (ensuring there is representation from different ages, sex, ethnicity, education, socioeconomic status) who are suitable for the IONA LCS are invited to participate.

Brief summary: Understanding more about how diseases that cause dementia develop is critical as the number of people living with, or affected by, dementia in Scotland continues to grow. The IONA Longitudinal Cohort Study (LCS) has been set up to gather information about people's cognitive health (their memory and thinking abilities), their lifestyle and health risk factors for future dementia (such as hearing loss and obesity), genetics and disease biomarkers, over a number of years. The IONA LCS has three main objectives: Firstly to develop this cohort that is well characterised (also known as being "well-phenotyped") that represent the Scottish population (taking into consideration age, sex, ethnicity and education). The second objective is to use this data to build disease models to better understand trajectories of diseases, and identify any sub-populations who have different (i.e. better, worse) disease trajectories. Finally the third objective for IONA LCS is to offer people an optional consent to hear about future studies they may be interested in taking part in.

Detailed description: IThe IONA Longitudinal Cohort Study (LCS) will provide a well-phenotyped (combining data on risk factors for dementia, cognitive assessment results, disease biomarkers and genetics) population representative of the Scottish population aged 50 and above across the spectrum of risk for, and the earliest disease stages of, AD dementia and other neurodegenerative conditions. Recent therapeutic successes in the treatment of Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild AD, as well as progressions in diagnostic tools such as blood-based biomarkers, has energised the field to develop more specific diagnostics and therapies following the best principles of precision medicine. Large, 'real world' cohorts are needed to understand whether these, and other future breakthroughs, are valid in real world populations away from highly selective clinical trials. Precision medicine requires identification of disease sub-populations who share similar diagnostic profiles that reflect similar disease mechanisms and hence are likely to respond consistently to specific therapeutic interventions. This will require detailed clinical, genetic and biological phenotyping. IONA LCS will recruit uniquely in Scotland and will ensure that a large, diverse, real-world population will be available to drive developments globally of more accurate diagnostics and accelerate the development of new disease modifying therapies.

Eligibility criteria: * Age at least 50 years.
* Living in Scotland.
* Able to read and write and with minimum 7 years of formal education.
* Have a study partner who is aged 18 years or older.
* Have capacity to provide informed consent at baseline.
* Able to speak English to a level where the cognitive assessments can be completed.

Primary outcomes:
measure: Change over time on the IONACog (a composite neuropsychological battery)
timeFrame: 10 years
measure: (Enhanced Phenotype only) Change over time in cerebrospinal fluid amyloid beta-42
timeFrame: 10 years
measure: (Enhanced Phenotype only) Change over time in cerebrospinal fluid phosphorylated tau 181
timeFrame: 10 years
measure: (Enhanced Phenotype only) Change over time in cerebrospinal fluid total tau
timeFrame: 10 years
Secondary outcomes:
measure: Change over time in dependency (as measured by the Stern Dependency Scale)
timeFrame: 10 years
measure: Change over time in caregiver burden (as measured by the Zarit Burden Index)
timeFrame: 10 years
measure: Change over time in functional impairment (as measured by the Amsterdam Instrumental Activities of Daily Living)
timeFrame: 10 years
measure: Change over time in quality of life (as measured by the QoL-AD)
timeFrame: 10 years
measure: (Enhanced Phenotype only) impact of disclosure of Alzheimer's disease biomarkers as measured by the Impact of Events scale-6.
timeFrame: 10 years
Other outcomes:
Locations:
city: Edinburgh
country: United Kingdom
facility: Scottish Brain Sciences Arran Facility
state: Lothian
Study officials:
References: